Changzhou Qianhong Biopharma CO.,LTD (SHE:002550)
China
· Delayed Price · Currency is CNY 5.47
-0.04 (-0.73%)
Feb 21, 2025, 3:04 PM CST
SHE:002550 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 1,551 | 1,809 | 2,302 | 1,874 | 1,667 | 1,674 | Upgrade
|
| Other Revenue | 5.17 | 5.17 | 1.13 | 1.02 | 0.54 | 1.26 | Upgrade
|
| Revenue | 1,556 | 1,814 | 2,304 | 1,875 | 1,668 | 1,675 | Upgrade
|
| Revenue Growth (YoY) | -26.63% | -21.24% | 22.86% | 12.43% | -0.45% | 26.74% | Upgrade
|
| Cost of Revenue | 764.2 | 1,045 | 1,419 | 1,045 | 880.42 | 877.01 | Upgrade
|
| Gross Profit | 791.73 | 768.81 | 884.31 | 829.44 | 787.19 | 798.14 | Upgrade
|
| Selling, General & Admin | 442.39 | 521.42 | 541.03 | 587.29 | 483.04 | 477.71 | Upgrade
|
| Research & Development | 104.84 | 97.08 | 88.31 | 71.18 | 69.14 | 65.38 | Upgrade
|
| Other Operating Expenses | 18.85 | 15.06 | 17.1 | 18.35 | 19.96 | 18.6 | Upgrade
|
| Operating Expenses | 481.76 | 614.55 | 661.74 | 677.06 | 577.18 | 560.16 | Upgrade
|
| Operating Income | 309.97 | 154.26 | 222.56 | 152.38 | 210.01 | 237.99 | Upgrade
|
| Interest Expense | -5.93 | -5.93 | -5.23 | -1.66 | -8.44 | -18.72 | Upgrade
|
| Interest & Investment Income | 20.81 | 19.3 | 5.64 | 1.6 | 21.61 | 107.58 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.26 | 1.26 | 74.02 | -5.4 | -17.71 | 4.36 | Upgrade
|
| Other Non Operating Income (Expenses) | -31.02 | -1.83 | -0.02 | 52.55 | -378.37 | -38.87 | Upgrade
|
| EBT Excluding Unusual Items | 295.1 | 167.07 | 296.97 | 199.48 | -172.91 | 292.34 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.61 | 0.77 | -4.59 | 0.64 | 0.44 | 0.33 | Upgrade
|
| Gain (Loss) on Sale of Assets | 25.35 | 25.35 | 57.59 | - | - | -0.03 | Upgrade
|
| Asset Writedown | -7.72 | -7.77 | -0.24 | -0.46 | -1.6 | -0.42 | Upgrade
|
| Other Unusual Items | 18.11 | 18.11 | 10.6 | 9.72 | 4.95 | 8.29 | Upgrade
|
| Pretax Income | 332.45 | 203.52 | 360.33 | 209.38 | -169.12 | 300.51 | Upgrade
|
| Income Tax Expense | 42.83 | 24.85 | 40.42 | 23.04 | -21.49 | 43.59 | Upgrade
|
| Earnings From Continuing Operations | 289.62 | 178.67 | 319.91 | 186.34 | -147.63 | 256.91 | Upgrade
|
| Minority Interest in Earnings | 3.97 | 3.19 | 3.5 | -5.26 | 15.61 | 5.65 | Upgrade
|
| Net Income | 293.59 | 181.86 | 323.41 | 181.08 | -132.02 | 262.56 | Upgrade
|
| Net Income to Common | 293.59 | 181.86 | 323.41 | 181.08 | -132.02 | 262.56 | Upgrade
|
| Net Income Growth | 16.10% | -43.77% | 78.60% | - | - | 18.62% | Upgrade
|
| Shares Outstanding (Basic) | 1,281 | 1,299 | 1,294 | 1,207 | 1,200 | 1,250 | Upgrade
|
| Shares Outstanding (Diluted) | 1,281 | 1,299 | 1,294 | 1,207 | 1,200 | 1,250 | Upgrade
|
| Shares Change (YoY) | -2.38% | 0.41% | 7.16% | 0.58% | -4.01% | -3.98% | Upgrade
|
| EPS (Basic) | 0.23 | 0.14 | 0.25 | 0.15 | -0.11 | 0.21 | Upgrade
|
| EPS (Diluted) | 0.23 | 0.14 | 0.25 | 0.15 | -0.11 | 0.21 | Upgrade
|
| EPS Growth | 18.93% | -44.00% | 66.67% | - | - | 23.53% | Upgrade
|
| Free Cash Flow | 505.42 | 433 | -142.46 | 13.19 | 254.74 | 60.87 | Upgrade
|
| Free Cash Flow Per Share | 0.39 | 0.33 | -0.11 | 0.01 | 0.21 | 0.05 | Upgrade
|
| Dividend Per Share | 0.120 | 0.120 | 0.120 | 0.120 | 0.120 | 0.250 | Upgrade
|
| Dividend Growth | 0% | 0% | 0% | 0% | -52.00% | 108.33% | Upgrade
|
| Gross Margin | 50.88% | 42.38% | 38.39% | 44.24% | 47.20% | 47.65% | Upgrade
|
| Operating Margin | 19.92% | 8.50% | 9.66% | 8.13% | 12.59% | 14.21% | Upgrade
|
| Profit Margin | 18.87% | 10.02% | 14.04% | 9.66% | -7.92% | 15.67% | Upgrade
|
| Free Cash Flow Margin | 32.48% | 23.87% | -6.18% | 0.70% | 15.28% | 3.63% | Upgrade
|
| EBITDA | 378.98 | 221.45 | 287.33 | 221.82 | 280.26 | 303.46 | Upgrade
|
| EBITDA Margin | 24.36% | 12.21% | 12.47% | 11.83% | 16.81% | 18.12% | Upgrade
|
| D&A For EBITDA | 69 | 67.19 | 64.76 | 69.43 | 70.25 | 65.47 | Upgrade
|
| EBIT | 309.97 | 154.26 | 222.56 | 152.38 | 210.01 | 237.99 | Upgrade
|
| EBIT Margin | 19.92% | 8.50% | 9.66% | 8.13% | 12.59% | 14.21% | Upgrade
|
| Effective Tax Rate | 12.88% | 12.21% | 11.22% | 11.00% | - | 14.51% | Upgrade
|
| Revenue as Reported | 1,556 | 1,814 | 2,304 | 1,875 | 1,668 | 1,675 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.